France remains the European “leader” in general and pharma levies

French pharma trade group Leem (Les Entreprises du Medicament) has published its annual survey on the taxation of the pharmaceutical industry, compared to that of other European countries.

This shows that France remains the European “leader” in general and sectoral levies, a context that threatens the sector's investment capacity in research and production of medicines.

The Leem calls for this situation to be urgently rectified as part of a “new deal” to rebuild the attractiveness of France, its health sovereignty, the competitiveness of businesses and the conditions of patient access to medicines. The mission of the pharmaceutical industry, which is to prevent, treat and save lives, can only be ensured in a sustainable economic environment favorable to investment by companies that develop and produce medicines, it contends.